Multiple securities law firms, including Robbins Geller Rudman & Dowd LLP and Rosen Law Firm, have filed class action lawsuits against PROCEPT BioRobotics, alleging the company used undisclosed bulk-order discounting that inflated reported U.S. handpiece sales and conflicted with prior guidance between February 2024 and February 2026. The lawsuits claim the discount program pulled sales forward, left more than 10,000 excess handpiece units in the field, and exposed investors to previously undisclosed operational and financial risks tied to inventory imbalances. These allegations could reshape the investment narrative for PROCEPT BioRobotics, which previously projected $608.2 million in revenue and $77.8 million in earnings by 2029, requiring 23.6% annual revenue growth and a $180.3 million earnings improvement from a current loss of $102.5 million. The legal overhang adds uncertainty around reported growth quality, future guidance, and how quickly Aquablation usage can normalize once field inventory is addressed.
Procept Biorobotics CorpClass action lawsuits allege undisclosed discounting inflated sales and misled investors, creating legal overhang and uncertainty.